B O O K - American College of Rheumatology

More documents

Recommendations

Info

ACR/ARHP Poster Session C 1865. Measuring Therapeutic Adherence in Systemic Lupus Erythematosus (SLE) Using the Medication Event Monitoring System (MEMS®). Maria F. Marengo, Christian A. Waimann, Sofia de Achaval, Vanessa L. Cox, Araceli Garcia Gonzalez, Marsha N. Richardson and Maria E. Suarez-Almazor, The University of Texas M. D. Anderson Cancer Center, Houston, TX. 1866. Mycophenolate Mofetil (MMF): Physician Prescribing Practices. Seema Malani 1 and Ellen M. Ginzler 2 , 1 SUNY Downstate Medical Center, Brooklyn, NY, 2 SUNY-Downstate Medical Center, Brooklyn, NY. 1867. Novel Cardiovascular Risk Prediction Models in Patients with Systemic Lupus Erythematosus. Vivian K. Kawai 2 , Annette M. Oeser 4 , Joseph Solus 3 , Young H. Rho 3 , Paolo Raggi 1 , Aihua Bian 3 , Tebeb Gebretsadik 3 , Ayumi Shintani 3 and C. Michael Stein 2 , 1 Emory University, 2 Vanderbilt University, Nashville, TN, 3 Vanderbilt University, 4 VUMC 23 rd Ave South Pierce, Nashville, TN. 1868. Optimal Frequency of Visits for SLE Patients To Capture Disease Activity over Time. Dominique Ibañez 3 , Dafna D. Gladman 2 and Murray B. Urowitz 1 , 1 The Toronto Western Hospital, Toronto, ON, Canada, 2 Toronto Western Hospital, Toronto, ON, Canada, 3 University of Toronto Lupus Clinic, Toronto Western Hospital, Toronto, ON, Canada. 1869. Optimal Frequency of Visits To Capture Disease Activity over Time in SLE Patients with Varying Levels of Disease Activity. Dominique Ibanez 2 , Murray B. Urowitz 3 and Dafna D. Gladman 1 , 1 Toronto Western Hospital, Toronto, ON, Canada, 2 University of Toronto Lupus Clinic, Toronto Western Hospital, 3 University of Toronto Lupus Clinic, Toronto Western Hospital, Toronto, ON, Canada. 1870. Performance of Anti-Nucleosome, Anti-C1q and Anti-dsDNA Antibodies for the Diagnosis of Concurrent Disease Activity of Systemic Lupus Erythematosus. Chi Chiu Mok, Ling Yin Ho, Hoi Wah Leung and Lap Gate Wong, Tuen Mun Hospital. 1871. Predictive Value of High Levels of Antinuclear Antibodies in People without Other Feature of Autoinmunity. A Prospective Study. Ignacio Villa-Blanco 4 , Marcos Lopez-Hoyos 1 , Ana Ruibal 2 and Jaime Calvo-Alen 3 , 1 Hospital “Marques de Valdecilla”, 2 Hospital “Txagorritxu”, 3 Hospital Sierrallana, Torrelavega, Spain, 4 Hospital Sierrallana, Spain. 1872. Preliminary Comparison of Health-Related Quality of Life in Children with Lupus across Different Continents. Lakshmi Nandini Moorthy 14 , Claudia Saad-Magalhães 1 , Juliana Oliveira Sato 1 , Claudio A. Len 10 , Maria O. Hilário 10 , Flavio Sztajnbok 9 , Rozana Gasparello de Almeida 9 , Feng Qi Wu 2 , Xiaolan L. Huang 2 , Fernanda Falcini 13 , Donato Rigante 11 , Rolando Cimaz 12 , Jordi Antón Lopez 8 , Consuelo Modesto 7 , Rubén J. Cuttica 5 , Lisette W. A. van Suijlekom-Smit 3 , Marieke H. Otten 3 , Maria J. Baratelli 14 , Margaret G. E. Peterson 6 , Afton L. Hassett 15 and Thomas J. A. Lehman 4 , 1 Botucatu Medical School - São Paulo State University, Brazil, 2 Capital Institute of Pediatrics, China, 3 Erasmus MC, Sophia Childrens Hospital, The Netherlands, 4 Hosp for Special Surgery, New York, NY, 5 Hospital de Pediatría Pedro de Elizalde, Argentina, 6 Hospital for Special Surgery, 7 Hospital Infantil Valle de Hebron, Spain, 8 Hospital Sant Joan de Déu, Spain, 9 Universidade do Estado do Rio de Janeiro, Brazil, 10 Universidade Federal de São Paulo, Brazil, 11 Università Cattolica Sacro Cuore, Italy, 12 University of Firenze, Firenze, Italy, 13 University of Florence, Florence, Italy, 14 University of Medicine and Dentistry of NJ - Robert Wood Johnson Medical School, New Brunswick, NJ, 15 University of Michigan Medical School, Ann Arbor, MI. 1873. Prevalence and Risk Factors of Glucocorticoid-Induced Diabetes Mellitus in Patients with Systemic Lupus Erythematosus. You Jung Ha 1 , Kwang-Hoon Lee 2 , Se-jin Jung 1 , Yoon Kang 1 , Min-Chan Park 3 , Sang-Won Lee 1 , Soo Kon Lee 1 and Yong-Beom Park 1 , 1 Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of, 2 Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of, 3 Gangnam Severance Hospital, Seoul, Korea, Republic of. 1874. Prolonged Serologically Active Clinically Quiescent (SACQ) Systemic Lupus Erythematosus (SLE): Novel Predictors of Flare? Amanda Steiman 1 , Murray B. Urowitz 2 , Joan E. Wither 4 , Dominique Ibañez 1 , Timothy Li 3 and Dafna D. Gladman 1 , 1 Toronto Western Hospital, Toronto, ON, Canada, 2 Toronto Western Hospital, Toronto, ON, Canada, 3 Toronto Western Hospital, 4 University Health Network, Toronto, ON, Canada. 1875. Racial Disparities in Treatment Preferences among Lupus Patients. Ernest R. Vina, Christopher M. Masi, Stephanie L. Green and Tammy O. Utset, University of Chicago Medical Center, Chicago, IL. 1876. Risk Factors Associated with the Presence of Pneumonia in Patients with Lupus Erythematosus (SLE): A Nested Case- Control Study. Iñigo Rúa-Figueroa 1 , Francisco J. Nóvoa 2 , Celia Erausquin 2 , Miguel Garcia-Bello 2 , Felipe Rodríguez de Castro 2 , Juan C. Quevedo 2 , Isabel García-Laorden 2 , Carlos Rodriguez- Gallego 2 , Felix Francisco 2 and Carlos Rodriguez-Lozano 2 , 1 Hospital Dr Negrin, Las Palmas GC, Spain, 2 Hospital Dr Negrin. 1877. SLE and Atherosclerotic Risk Factors by Ethnicity and Geographic Distribution at Inception in a International Cohort of SLE. Murray B. Urowitz 33 , Dafna D. Gladman 22 , Dominique Ibanez 32 , Caroline P. Gordon 29 , Sang-Cheol Bae 6 , Ann E. Clarke 15 , Sasha R. Bernatsky 15 , F. Jorge Sanchez-Guerrero 9 , John G. Hanly 19 , David A. Isenberg 24 , Anisur Rahman 25 , Paul R. Fortin 33 , Daniel J. Wallace 1 , Ellen M. Ginzler 20 , Joan T. Merrill 18 , Graciela S. Alarcón 28 , Barri J. Fessler 23 , Ian N. Bruce 13 , Gunnar K. Sturfelt 27 , Ola Nived 27 , Kristjan Steinsson 12 , Munther A. Khamashta 21 , Michelle A. Petri 2 , Rosalind Ramsey-Goldman 17 , Susan Manzi 34 , Mary Anne Dooley 31 , Ronald V. Vollenhoven 11 , Cynthia B. Aranow 4 , Thomas Stoll 10 , Manuel Ramos 7 , Kenneth C. Kalunian 26 , Asad A. Zoma 5 , Guillermo Ruiz-Irastorza 8 , Peter J. Maddison 16 , Diane L. Kamen 14 , S. Sam Lim 3 and Christine A. Peschken 30 , 1 West Hollywood, CA, 2 Timonium, MD, 3 Emory University, Atlanta, GA, 4 Feinstein Institute, Manhasset, NY, 5 Hairmyres Hospital, East Kilbride, United Kingdom, 6 Hanyang University Medical Center, Seoul, Korea, Republic of, 7 Hospital Clinico I Provincial, 8 Hospital de Cruces, Universidad del Pais Vasco, 9 Instituto Nacional Nutricion, Mexico City, DF, Mexico, 10 Kantansspital Schaffhausen, Schaffhausen, Switzerland, 11 Karolinska University Hospital, 12 Landspitalinn University Hospital, 13 Manchester Royal Infirmary, Manchester, United Kingdom, 14 Medical University of South Carolina, Charleston, SC, 15 Montreal General Hospital, Montreal, QC, Canada, 16 North West Wales NHS Trust, Colwyn Bay, United Kingdom, 17 Northwestern University, Chicago, IL, 18 Oklahoma Medical Research Foundation, Oklahoma City, OK, 19 Queen Elizabeth II Health Services Center, Halifax, NS, Canada, 20 SUNY-Downstate Medical Center, Brooklyn, NY, 21 The Rayne Institute, London, United Kingdom, 22 Toronto Western Hospital, Toronto, ON, Canada, 23 UAB Rheumatology, Birmingham, AL, 24 UCL Div of Medicine, London, United Kingdom, 25 UCL Div of Medicine, 26 UCSD School of Medicine, La Jolla, CA, 27 University Hospital Lund, Lund, Sweden, 28 University of Alabama, Oakland, 264 2010 Program Book
ACR/ARHP Poster Session C CA, 29 University of Birmingham, Birmingham, United Kingdom, 30 University of Manitoba, Winnipeg, MB, Canada, 31 University of North Carolina at Chapel Hill, Chapel Hill, NC, 32 University of Toronto Lupus Clinic, Toronto Western Hospital, 33 University of Toronto Lupus Clinic, Toronto Western Hospital, Toronto, ON, Canada, 34 West Penn Allegheny Health System, Pittsburgh, PA. 1878. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI- 2K) Responder Index (SRI)-50: A Valid Index for Measuring Improvement in Disease Activity. Zahi Touma 2 , Dafna D. Gladman 1 , Dominique Ibañez 2 and Murray B. Urowitz 2 , 1 Toronto Western Hospital, Toronto, ON, Canada, 2 University of Toronto Lupus Clinic, Toronto Western Hospital, Toronto, ON, Canada. 1879. The Relative Importance of Current Versus Past Use of Medication in Excess Rates of Adverse Cardiovascular Events among Patients with SLE. Michelle A. Petri 1 and Laurence S. Magder 2 , 1 Timonium, MD, 2 Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD. 1880. Validation of CLASI Scale with Lupus Disease Activity, Damage, Body Image and Quality of Life. Meenakshi Jolly 1 , Rachel A. Mikolaitis 3 , Thomas F. Cash 2 and Joel A. Block 2 , 1 Rush University Medical Center, Chicago, IL, 2 Rush University Medical Center, Chicago, IL, 3 Rush University Medical Center. 1881. Validity of the ACR Criteria and SLICC Proposed Criteria for the Diagnosis and Classification of Systemic Lupus Erythematosus. Felipe Rodriguez-García 2 , Karina Santana- de Anda 2 , Ali Duarte- García 1 , Virginia Pascual-Ramos 2 , Gabriela Hernández-Medina 2 , Tatiana Rodríguez-Reyna 2 and Jorge Sanchez-Guerrero 3 , 1 Instituto Nacional ce Ciencias Medicas y Nutricion Salvador Zubiran, 2 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, 3 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico. 1882. Work Disability, Lost Productivity and Associated Risk Factors in Patients Diagnosed with Systemic Lupus Erythematosus (SLE). Tammy O. Utset 5 , Barbara M. Segal 6 , Laura Trupin 4 , Sarika Ogale 1 , Ellen Herberich 2 and Kenneth C. Kalunian 3 , 1 Genentech, 2 Harris Interactive, 3 UCSD School of Medicine, La Jolla, CA, 4 University of California, San Francisco, 5 University of Chicago, Chicago, IL, 6 University of Minnesota, Minneapolis, MN. Sjögren’s Syndrome 1883. Activation of Innate Immunity and Sjögren’s Syndrome Development. Seshagiri Rao Nandula 1 , Yogesh M. Scindia 2 , Harini Bagavant 1 and Umesh S. Deshmukh 2 , 1 University of Virginia, Charlottesville, VA, 2 University of Virginia. 1884. Anticentromere Antibodies (ACA)-Positive Systemic Sclerosis (SSc) Patients with Sjögren’s Syndrome: A Distintict Subset at High Risk of Lymphoma. Chiara Baldini, Sara Grossi, Alessandra Della Rossa, Nicoletta Luciano, Marica Doveri, Antonio Gaetano Tavoni and Stefano Bombardieri, Rheumatology Unit, Department of Internal Medicine, University of Pisa, Italy. 1885. Association between Lymphotoxin Alpha Genetic Variants and Primary Sjögren’s Syndrome in Scandinavian Samples. Anne Isine Bolstad 1 , Stephanie Le Hellard 2 , Gudlaug Thora Kristjansdottir 4 , Gunnel Nordmark 4 , Lilian Vasaitis 8 , Marika Kvarnström 6 , Christopher Sjöwall 13 , Svein Joar Auglænd Johnsen 9 , Per Eriksson 12 , Roald Omdal 10 , Johan G. Brun 5 , Marie Wahren-Helenius 6 , Elke Theander 7 , Ann-Christine Syvänen 3 , Lars Rönnblom 4 and Roland Jonsson 11 , 1 Department of Clinical Dentistry-Periodontics, University of Bergen, Bergen, Norway, 2 Department of Clinical Medicine, University of Bergen, Center of Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway, 3 Department of Medical Sciences, Molecular Medicine, Uppsala University, Uppsala, Sweden, 4 Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, 5 Department of Medicine, Section of Rheumatology, University of Bergen, Bergen, Norway, 6 Karolinska Institutet, Stockholm, Sweden, 7 Malmö University Hospital, Malmö, Sweden, 8 Section of Rheumatology, Uppsala University, Uppsala, Sweden, 9 Stavanger University Hospital, Stavanger, Norway, 10 Stavanger University Hospital, Stavanger, Norway 11 The Gade Institute, University of Bergen, Bergen, Norway, 12 University Hospital Linköping, Sweden, Linköping, Sweden, 13 University Hospital, Linköping, Linköping, Sweden. 1886. B-Cell Profiling Using Multi-Color Flow Cytometry as Biomarker of Disease Progression in Primary Sjogren’s Syndrome (pSS). Mustimbo Roberts 2 , Craig Maguire 3 , Alex Rosenberg 3 , Andreea Coca 2 , Jennifer H. Anolik 1 and Iñaki Sanz 2 , 1 University of Rochester, Rochester, NY, 2 University of Rochester Medical Center, Rochester, NY, 3 University of Rochester Medical Center. 1887. Best Scintigraphic Measures of Parotid Gland Dysfunction in Sjogren’s Syndrome. Anthony Keyes 4 , Julius Birnbaum 2 , John Petronis 1 and Alan N. Baer 3 , 1 Johns Holins University School of Medicine, 2 Johns Hopkins University, Baltimore, MD, 3 Johns Hopkins University, Baltimore, MD, 4 Johns Hopkins University School of Medicine. 1888. Clinical and Immunological Profile of Patients with Primary Sjogren Syndrome Who Developed B-Cell Lymphoma. Analysis of 1010 Spanish Patients (The GEMESS Cohort). Manuel Ramos-Casals 3 , Roser Solans 11 , Jose Rosas 6 , Maria Teresa Camps 2 , Antonio Gil 9 , Javier Del-Pino 10 , Carmen Hidalgo 12 , Jaime Calvo 4 , Maria Luisa Mico 8 , Roberto Perez-Alvarez 7 , Rafael Belenguer 1 and Lucio Pallares 5 , 1 Hospital 9 d’Octubre, València, Spain, 2 Hospital Carlos Haya, Malaga, Spain, 3 Hospital Clinic, Barcelona, Spain, 4 Hospital de Sierrallana, Torrelavega, Spain, 5 Hospital de Son Dureta, Palma de Mallorca, Spain, 6 Hospital de Vilajoyosa, Alicante, Spain, 7 Hospital do Meixoeiro, Vigo, Spain, 8 Hospital La Fe, Valencia, Spain, 9 Hospital La Paz, Madrid, Spain, 10 Hospital Universitario de Salamanca, Salamanca, Spain, 11 Hospital Vall d’Hebron, Barcelona, Spain, 12 Hospital Virgen de las Nieves, Granada, Spain. 1889. Clonal Analysis of Ig-Expressing Cells in Salivary Glands of Primary Sjögren’s Syndrome Patients after Anti-CD20 Treatment. Nishath Hamza 3 , Hendrika Bootsma 4 , Rodney P. E. Pollard 2 , Jiska M. Meijer 2 , Fred K. L. Spijkervet 2 , Arjan Vissink 2 , Hans G. M. Burgerhof 5 , Frans G. M. Kroese 1 , Cees G. M. Kallenberg 4 and Nicolaas A. Bos 1 , 1 Dept. of Cell Biology, Immunology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, 2 Dept. of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, 3 Dept. of Rheumatology and Clinical Immunology & Dept. of Cell Biology, Immunology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, 4 Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, 5 University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 2010 Program Book 265
Page 1 and 2:
program B O O K Pre-Conference Cour
Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
Page 11 and 12:
the written consent of the ACR is p
Page 13 and 14:
Shuttle Bus Service See shuttle sig
Page 15 and 16:
ACR Resource Center Hours: Sunday,
Page 17 and 18:
ACR Hotels + Map Complimentary shut
Page 19 and 20:
to the premier meeting in rheumatol
Page 21 and 22:
ACR Clinical Research Conference c/
Page 23 and 24:
4:20 PM Germinal Center Reactions A
Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
Page 27 and 28:
Upon completion of this session, pa
Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
Page 31 and 32:
B301 Dermatological Manifestations
Page 33 and 34:
Session Overview: The innate immune
Page 35 and 36:
Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
Page 39 and 40:
and insufficiency • recall source
Page 41 and 42:
Session Overview: The advent of bio
Page 43 and 44:
2:45 pm 641. Major Improvements in
Page 45 and 46:
5 University of Twente and Medisch
Page 47 and 48:
ACR/ARHP Combined Abstract Session
Page 49 and 50:
REF 25th Anniversary Celebration 2:
Page 51 and 52:
5:45 PM 699. Defining Latent and/or
Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
Page 59 and 60:
• discuss the principles of early
Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
Page 65 and 66:
ACR Plenary Session II: Discovery 2
Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
Page 69 and 70:
Session Overview: As a clinical edu
Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
Page 77 and 78:
2:45 PM 1405. Development of a Visi
Page 79 and 80:
4:30 PM Anti-citrullinated Protein
Page 81 and 82:
of Experimental Orthopedics, Univer
Page 83 and 84:
5:30 PM 1438. Mortality/Morbidity i
Page 85 and 86:
5:30 PM 1456. Belimumab, a BLyS-Spe
Page 87 and 88:
Develly 5 , Bernardo L. F. Fernande
Page 89 and 90:
7:30 PM Role of IL-1 in Human Artic
Page 91 and 92:
• compare the prevalence and epid
Page 93 and 94:
6:45 PM Macrophage Activation Syndr
Page 95 and 96:
Page 97 and 98:
Session Overview: This roundtable d
Page 99 and 100:
B303 Scleroderma: Systemic Sclerosi
Page 101 and 102:
9:00 - 10:30 am - Poster Hall Morni
Page 103 and 104:
• describe the role of IL-1 and I
Page 105 and 106:
Session Overview: For the clinician
Page 107 and 108:
• identify the aspects for day-to
Page 109 and 110:
ACR Study Groups 1:00 - 2:00 PM B30
Page 111 and 112:
Session Overview: Ultrasound and ma
Page 113 and 114:
Session Overview: Fifty percent of
Page 115 and 116:
1:20 PM Academic Rheumatology Seth
Page 117 and 118:
ACR Concurrent Abstract Sessions 2:
Page 119 and 120:
3:00 PM 2110. Rheumatologists on th
Page 121 and 122:
2:45 PM 2133. Reasons for Decline i
Page 123 and 124:
Session Overview: We are witnessing
Page 125 and 126:
Session Overview: Systemic sclerosi
Page 127 and 128:
Oaks, CA, 2 Amgen Inc., San Francis
Page 129 and 130:
5:00 PM 2176. A Role of Autoimmune
Page 131 and 132:
4:30 PM 2198. Association between V
Page 133 and 134:
ARHP Concurrent Sessions 4:30 - 6:0
Page 135 and 136:
THURSDAY, NOVEMBER 11, 2010 ACR/ARH
Page 137 and 138:
• apply these basic statistics to
Page 139 and 140:
9:15 AM The ACR/EULAR Definition of
Page 141 and 142:
Immunology, Oslo University Hospita
Page 143 and 144:
9:15 AM 2239. Factors Associated wi
Page 145 and 146:
Page 147 and 148:
Mikkel Østergaard 6 , Paul Emery 4
Page 149 and 150:
Ende 4 , 1 Department of Rheumatolo
Page 151 and 152:
ACR Poster Session A Cytokines, Med
Page 153 and 154:
ACR Poster Session A 51. Associatio
Page 155 and 156:
ACR Poster Session A 83. Respirator
Page 157 and 158:
ACR Poster Session A 121. Bone Dens
Page 159 and 160:
ACR Poster Session A 142. The Intra
Page 161 and 162:
ACR Poster Session A 171. Early Pro
Page 163 and 164:
ACR Poster Session A Pediatric Rheu
Page 165 and 166:
ACR Poster Session A 233. Prevalenc
Page 167 and 168:
ACR Poster Session A 266. Subtype S
Page 169 and 170:
ACR Poster Session A 297. Body Weig
Page 171 and 172:
ACR Poster Session A 325. Patient R
Page 173 and 174:
ACR Poster Session A 356. Influence
Page 175 and 176:
ACR Poster Session A 383. Efficacy
Page 177 and 178:
ACR Poster Session A 409. Rituximab
Page 179 and 180:
ACR Poster Session A 441. Recombina
Page 181 and 182:
ACR Poster Session A 465. Immunoglo
Page 183 and 184:
ACR Poster Session A 496. IRF8 Alle
Page 185 and 186:
ACR Poster Session A 521. DC-STAMP
Page 187 and 188:
ACR Poster Session A 546. Prevalenc
Page 189 and 190:
ACR Poster Session A 571. Epidemiol
Page 191 and 192:
ACR Poster Session A 599. Validatio
Page 193 and 194:
ACR/ARHP Poster Session B Halls B1
Page 195 and 196:
ACR Poster Session B 767. Economic
Page 197 and 198:
ACR/ARHP Poster Session B 792. The
Page 199 and 200:
ACR/ARHP Poster Session B Universit
Page 201 and 202:
ACR/ARHP Poster Session B 848. Cell
Page 203 and 204:
ACR/ARHP Poster Session B 886. Scre
Page 205 and 206:
ACR/ARHP Poster Session B 909. Regu
Page 207 and 208:
ACR/ARHP Poster Session B 935. The
Page 209 and 210:
ACR/ARHP Poster Session B 967. Frac
Page 211 and 212:
ACR Poster Session B 993. Early Exp
Page 213 and 214:
ACR/ARHP Poster Session B 1022. Com
Page 215 and 216: ACR/ARHP Poster Session B 1055. Son
Page 217 and 218: ACR Poster Session B 1084. Gene Exp
Page 219 and 220: ACR/ARHP Poster Session B 1111. Inc
Page 221 and 222: ACR Poster Session B hiroshima Memo
Page 223 and 224: ACR/ARHP Poster Session B 1166. Pre
Page 225 and 226: ACR/ARHP Poster Session B 1199. Typ
Page 227 and 228: ACR/ARHP Poster Session B 1225. Phy
Page 229 and 230: ACR/ARHP Poster Session B 1262. Lat
Page 231 and 232: ACR/ARHP Poster Session B 1294. End
Page 233 and 234: ACR/ARHP Poster Session B 1321. Cha
Page 235 and 236: ACR/ARHP Poster Session C Halls B1
Page 237 and 238: ACR/ARHP Poster Session C 1495. S10
Page 239 and 240: ACR/ARHP Poster Session C 1524. Inc
Page 241 and 242: ACR/ARHP Poster Session C 1555. Pro
Page 243 and 244: ACR/ARHP Poster Session C 1583. Ass
Page 245 and 246: ACR/ARHP Poster Session C 1596. Gen
Page 247 and 248: ACR/ARHP Poster Session C 1622. Flu
Page 249 and 250: ACR/ARHP Poster Session C Miscellan
Page 251 and 252: ACR/ARHP Poster Session C L. Woodwa
Page 253 and 254: ACR/ARHP Poster Session C 1692. Res
Page 255 and 256: ACR/ARHP Poster Session C 1719. Los
Page 257 and 258: ACR/ARHP Poster Session C 1749. Con
Page 259 and 260: ACR/ARHP Poster Session C 1780. Tow
Page 261 and 262: ACR/ARHP Poster Session C 1804. Eff
Page 263 and 264: ACR/ARHP Poster Session C Immunolog
Page 265: ACR/ARHP Poster Session C 2 Departm
Page 269 and 270: ACR/ARHP Poster Session C 1900. IL-
Page 271 and 272: ACR/ARHP Poster Session C 1930. Cor
Page 273 and 274: ACR/ARHP Poster Session C 1958. The
Page 275 and 276: ACR/ARHP Poster Session C 1988. Cha
Page 277 and 278: ACR/ARHP Poster Session C 2015. CpG
Page 279 and 280: ACR/ARHP Poster Session C 2038. Pri
Page 281 and 282: ACR/ARHP Poster Session C 2070. Ass
Page 283 and 284: REF Industry Roundtable-supported S
Page 285 and 286: REF Industry Roundtable-supported S
Page 287 and 288: INDUSTRY-SUPPORTED POST-CONFERENCE
Page 289 and 290: 2010 ACR/ARHP Annual Meeting Leader
Page 291 and 292: 2010 ACR/ARHP Annual Meeting Leader
Page 293 and 294: FLOOR PLANS 2010 Program Book 291
Page 295 and 296: VISIT THE EXHIBIT HALL New and inno
Page 297 and 298: EXHIBITORS La Lettre Du Rhumatologu
Page 299 and 300: ACKNOWLEDGEMENTS The ACR, the ARHP
Page 301 and 302: ACR/ARHP/REF STAFF LISTING Administ
Page 303 and 304: A Ahmed, Rafi, PhD T cell Memory .
Page 305 and 306: Cooper, Max D, MD Introduction . .
Page 307 and 308: Gerlag, Danielle Marie, MD, PhD The
Page 309 and 310: Physical Examination Skills for Imp
Page 311 and 312: Meroni, Pierluigi, MD Autoantibodie
Page 313 and 314: Rogers, Joan C, PhD, OTR/ L Underst
Page 315 and 316: Terkeltaub, Robert, MD Crystallizin
Page 317 and 318:
A Aarden, L 1825 Aarrass, S 1519, 1
Page 319 and 320:
Bakker, AAB 1095 Barendregt, B 753
Page 321 and 322:
Boutin-Le Thi Huong, D 478 Bout-Tab
Page 323 and 324:
Chatham, WW 457, 1146, 1454, 1457,
Page 325 and 326:
Daudon, M 875 Daugas, E 2009 Davatc
Page 327 and 328:
Ehst, B 758 Eicher, JL 688 Eisen, S
Page 329 and 330:
Gabay, OH 1484 Gaber, T 630, 1418 G
Page 331 and 332:
Guan, M 965 Guañabens, N 975 Gudbj
Page 333 and 334:
Homme, CL 730 Honda, E 434 Hong, JY
Page 335 and 336:
Kambayashi, T 1354 Kamdar, AA 1160
Page 337 and 338:
Kuller, LH 71 Kumabe, M 1164 Kumaga
Page 339 and 340:
Looney, C 941 Looney, MR 609 Looney
Page 341 and 342:
McCarthy, GM 1109, 1306, 1426 McCau
Page 343 and 344:
Myouzen, K 1577 Mysiw, WJ 2096 Mysl
Page 345 and 346:
Pans, M 1834 Parra, ER 605, 887 Ped
Page 347 and 348:
Radka, S 1174 Radner, H 296, 1745 R
Page 349 and 350:
Sack, KE 1898 Sacli, SF 1312 Saddic
Page 351 and 352:
1463, 2071, 2140, 2141 Singh, K 212
Page 353 and 354:
Takahata, M 1492 Takasaki, Y 1731 T
Page 355 and 356:
636 van Dongen, CJJ 90 Van Doornum,
Page 357 and 358:
Witte, T 824, 1578, 1579, 2214 Witt
Page 359 and 360:
A α-galactosylceramide 505 A2A kno
Page 361 and 362:
Behcet’s syndrome 1284, 1288, 129
Page 363 and 364:
cost-utility 759, 1539 couples 1324
Page 365 and 366:
fibroblast like synoviocyte 27 fibr
Page 367 and 368:
impact 1063, 1325 inactive disease
Page 369 and 370:
methylation 826, 1253, 1489 methylt
Page 371 and 372:
233, 234, 240, 243, 252, 262, 268,
Page 373 and 374:
1599, 1600, 1603, 1605, 1606, 1609,
Page 375 and 376:
1226, 1227, 1229, 1230, 1231, 1233,
Page 377 and 378:
Abelson, Abby Goulder, MD Education
Page 379 and 380:
Massarotti, Elena M, MD Systemic Lu
Page 381 and 382:
ACR Annual Meeting fellowS-in-train
Page 383 and 384:
NOTES 2010 Program Book 381
Page 385 and 386:
Enbrel ® (etanercept) Brief Summar
Page 387 and 388:
Prescription Enbrel ® (etanercept)
show all

B O O K - American College of Rheumatology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?